The lncRNA H19 targeting agent BC-819 (H19-DTA) has completed clinical trials in ovarian [105], bladder [106], and pancreatic cancers [107] with favorable results, though it has not yet received clinical approval. Here, H19 is linked to pancreatic neoplasm.